



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 67139

Title: MTN B polymorphisms with CDKN2A and MGMT methylation status are associated with poor prognosis of colorectal cancer in Taiwan

Reviewer's code: 04907200

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Taiwan

Manuscript submission date: 2021-04-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-16 06:09

Reviewer performed review: 2021-04-19 07:42

Review time: 3 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This study indicated the novel genetic biomarkers, MTNR1B, combined with CDKN2A and MGMT gene methylation statuses, maybe a predictive tool for CRC prognosis. The researchers hypothesised that the influence of MTNR1B gene variation combined with the hypermethylation of CDKN2A and MGMT genes would predict the prognosis and provide clinical recommendations for optimal treatment of CRC. This study offers insights into novel genetic and epigenetic biomarkers for the prediction of CRC prognosis, and the findings could be used to individualise the treatment of patients with CRC. Since CRC is a high-incidence cancer, such a clinical research that investigated the new biomarkers of CRC is helpful. One concern is that adjusting for confounding factors such as obesity, a sedentary lifestyle, and unhealthy dietary habits in Table 4, 5 and 6 would be better for studying the effect of MTNR1B SNPs associated with 5-year OS of CRC patients, as this study mentioned. Secondly, the inclusion and exclusion criteria for this study seem to be unclear. Thirdly, it would be better to review format of the full text carefully, with respect to spaces between text and punctuation in the method.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 67139

Title: MTN B polymorphisms with CDKN2A and MGMT methylation status are associated with poor prognosis of colorectal cancer in Taiwan

Reviewer's code: 03940557

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: Taiwan

Manuscript submission date: 2021-04-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-19 08:53

Reviewer performed review: 2021-04-19 08:54

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

acceptable



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 67139

Title: MTN B polymorphisms with CDKN2A and MGMT methylation status are associated with poor prognosis of colorectal cancer in Taiwan

Reviewer's code: 03538879

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Chief Doctor, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Taiwan

Manuscript submission date: 2021-04-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-16 00:21

Reviewer performed review: 2021-04-21 01:02

Review time: 5 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

In general, this is a well-designed and mature retrospective trial. I only have a few comments for authors. 1. The introduction of CDKN2A and MGMT genes is abrupt. Please supplement more information about them and explain why choose these two genes for combination analysis. 2. Authors used Cox proportional-hazards models for to analyze the survival. The adjusted factors included age, sex, stage, adjuvant chemotherapy, tumour location, and the methylation status of the CDKN2A, MLH1 and MGMT genes. What about BMI and combined primary diseases? 3. The sample size is a concern. The wide 95%CI indicated poor stability.